GLP-1Research peptide

Liraglutide

Liraglutide is a once-daily acylated GLP-1 receptor agonist and one of the earliest GLP-1 analogs studied. Research spans glucose regulation, appetite signaling, and weight management endpoints.

Also known as: Victoza (brand), Saxenda (brand)

Technical information

Molecular weight

3751.2 g/mol

Half-life

~13 hours (subcutaneous)

Sequence

GLP-1 analog (Arg34, Lys26-N-palmitoyl-glutamate)

Common research doses

0.6-3.0 mg/day (research protocols)

Research areas

GLP-1 agonismGlucose regulationWeight managementAppetite research

For research purposes only. PepAssure provides vendor information as a verification service and does not endorse or recommend any specific use. Consult qualified research protocols and institutional review boards.